Who are Rubedo Life Sciences's investors?

Rubedo Life Sciences's investors include Alumni Ventures, Beiersdorf Innovation Fund, CDP Venture Capital, Evolution Ventures, IKJ Capital, Khosla Ventures, LongeVC, Modi Ventures and 3 more.

How much funding has Rubedo Life Sciences raised?

Rubedo Life Sciences has disclosed $40M raised across 1 round.

Rubedo Life Sciences

Founded 2018 · 32 employees on LinkedIn · 11 known investors

Find your way into Rubedo Life Sciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the Rubedo Life Sciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Rubedo Life Sciences develops therapeutics targeting aging by eliminating senescent cells to extend human healthspan. The company applies artificial intelligence and chemistry to drug discovery in the longevity and regenerative medicine space.

AI & Machine Learning Biotech Longevity Medical Devices

Founders & leadership

Julian KleinFounder

Marco QuartaFounder

Mark GallopFounder

Investors · 11

Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M

How we know: av.vc · Not right? Tell us

Beiersdorf Innovation Fundlisted by Beiersdorf Innovation FundHamburg · $550K – $5.5M

CDP Venture Capitallisted by CDP Venture CapitalRoma

How we know: CDP Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Evolution Ventureslisted by Evolution VenturesCupertino

IKJ Capitallisted by IKJ CapitalPalo Alto

How we know: IKJ Capital's portfolio page · Not right? Tell us

Khosla Ventureslisted by Khosla VenturesMenlo Park · $100K – $20M

How we know: Khosla Ventures's portfolio page · a partner's Signal profile · funding news · businesswire.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

LongeVClisted by LongeVCWashington D.C.

How we know: LongeVC's portfolio page · Not right? Tell us

Modi Ventureslisted by Modi VenturesHouston

How we know: Modi Ventures's portfolio page · Not right? Tell us

Moonstone Venture Capitallisted by Moonstone Venture CapitalMilan

Ahren Innovation CapitalreportedCambridge, Cambridgeshire

How we know: a partner's Signal profile · businesswire.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Refactor CapitalreportedBurlingame · $1M – $2M

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

$40M disclosed across 1 round · 2024

$40MSeries AApr 2024 · 2 sources
Ahren Innovation Capital (lead), Khosla Ventures (lead)
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Rubedo Life Sciences went on to found or lead other companies.

Uri LopatinBoard MemberFounded Assembly Biosciences +2 Paolo PriviteraInvestorFounded 1521 Capital +1

Related companies · 5

Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Korro BioKorro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.

Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies working in the same space as Rubedo Life Sciences.

In the news

Rubedo Life Sciences Raises $40M in Series A Financingfinsmes.com · Apr 2024

Investor News Grid - Rubedo Life Sciencesrubedolife.com · Jun 2022

Investors & News - Rubedo Life Sciencesrubedolife.com · Jun 2022

Frequently asked questions

What does Rubedo Life Sciences do?: Rubedo Life Sciences develops therapeutics targeting aging by eliminating senescent cells to extend human healthspan. The company applies artificial intelligence and chemistry to drug discovery in the longevity and regenerative medicine space.
Who are Rubedo Life Sciences's investors?: Rubedo Life Sciences's investors include Alumni Ventures, Beiersdorf Innovation Fund, CDP Venture Capital, Evolution Ventures, IKJ Capital, Khosla Ventures, LongeVC, Modi Ventures and 3 more.
How much funding has Rubedo Life Sciences raised?: Rubedo Life Sciences has disclosed $40M raised across 1 round.